September 2015 | Volume 14 | Issue 9 | Features | 1076 | Copyright © September 2015
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department
may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new
products. In addition, we will inform our readers about the latest drugs receiving Food and Drug Administration (FDA) approval.
Ferndale Healthcare®, Inc. announced that the the newest addition
to the Heliocare® line, Heliotop™ 360 Sunscreen. This mineral sunscreen formulated with Titanium Dioxide and Zinc Oxide, features the antioxidant, Fernblock® Polypodium leucotomosextract
(PLE). Heliotop™ 360 Sunscreen with SPF 50+ is a broad spectrum sunscreen protecting against UVA-UVB sun rays. It’s sunscreen protection with antioxidant benefits.
Taking Heliocare® Daily Use Antioxidant Formula daily* is a way to supplement topical sun protection.
FDA Approves Syneron Candela's PicoWay
The FDA has approved Syneron Candela’s PicoWay® picosecond
laser for the treatment of pigmented lesions. The PicoWay® device previously received FDA clearance for the removal of tattoos in November 2014 and was launched in the U.S. late in the fourth quarter 2014. Syneron Medical Ltd. also recently received Health Canada clearance of the PicoWay® picosecond laser for the treatment of pigmented lesions and tattoo removal.
PicoWay® is a dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay® technology to generate picosecond pulses for the treatment of pigmented lesions
and tattoos of all colors.